NCT01007149 - Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Asthma

Interventions

DRUG

omalizumab

Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.

DRUG

Placebo

Placebo was supplied in vials with solution for subcutaneous injection.

Trial Locations (10)

Novartis Investigative Site, Arnaud de Villeneuve

Novartis Investigative Site, Béthune

Novartis Investigative Site, Bordeaux

Novartis Investigative Site, Clamart

Novartis Investigative Site, Lyon

Novartis Investigative Site, Nantes

Novartis Investigative Site, Paris

Novartis Investigative Site, Strasbourg

Novartis Investigative Site, Suresnes

Novartis Investigative Site, Toulouse